The estimated proportion of patients who are expected to be eligible for cellular therapy based on HLA-A*02 allele and a range of MAGE-A4 positivity estimates (53%-82% of patients with SS) is summarized in Table 1. This evidence concerns the gene MAGEA4 and synovial sarcoma.